- Home
- WPAC vs UNCY Comparison
WPAC vs UNCY Comparison
Compare WPAC & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WPAC | UNCY |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 150.1M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WPAC | UNCY |
|---|---|---|
| Price | $10.09 | $4.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $29.60 |
| AVG Volume (30 Days) | 49.5K | ★ 767.1K |
| Earning Date | N/A | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52,701.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $3.93 |
| 52 Week High | $11.89 | $8.74 |
Technical Indicators
Market Signals| Indicator | WPAC | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 63.32 | 40.81 |
| Support Level | $10.03 | $3.93 |
| Resistance Level | $10.11 | $5.86 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 100.00 | 38.32 |
Price Performance
Historical ComparisonAbout WPAC White Pearl Acquisition Corp. Class A Ordinary Shares
White Pearl Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.